期刊文献+

冠状动脉慢血流与冠状动脉微循环障碍的相关性研究 被引量:31

Relationship Between Slow Coronary Flow and Coronary Microcirculatory Dysfunction in Relevant Patients
下载PDF
导出
摘要 目的:探讨冠状动脉(冠脉)慢血流(SCF)与冠脉微循环的相关性,以及SCF发生、发展的相关危险因素。方法:在接受冠脉造影的患者中,选择被诊断为SCF的32例为SCF组,冠脉血流正常和无明显狭窄病变的32例为对照组,分别记录和测定两组患者的一般资料和各项生化指标、高敏C反应蛋白(hs-CRP)、心肌梗死溶栓治疗临床试验(TIMI)血流帧数以及冠脉微循环阻力指数(IMR),分析各项指标与SCF的关系。结果:与对照组比较,SCF组患者的高密度脂蛋白胆固醇(HDL-C)和载脂蛋白-A1水平较低[(1.57±0.38)mmol/L vs(1.62±0.43)mmol/L,(1.41±0.31)mmol/L vs(1.57±0.38)mmol/L];hs-CRP水平较高[(3.63±1.67)μg/m L vs(1.74±0.75)μg/m L];IMR明显升高[(29.28±7.68)vs(24.94±6.67)],差异均有统计学意义(P<0.05)。且IMR与TIMI血流帧数及hs-CRP呈正相关(r=0.766,P=0.019;r=0.565,P<0.01)。结论 :(1)冠脉微循环功能障碍与SCF发生、发展呈相关性。(2)在冠脉微循环障碍中,炎症反应可能起到一定作用,HDL-C和载脂蛋白-A1水平的降低,可能也参与了冠脉微循环障碍的病理过程,从而在一定程度导致SCF。 Objective: To study the relationship between slow coronary flow (SCF) and coronary microcirculatory dysfunction in relevant patients and to explore the risk factors for SCF development. Methods: Our research was conducted in 2 groups: SCF group, the patients with coronary angiography confirmed diagnosis and Control group, the subjects with normal coronary flow. n=32 in each group. The general information, blood levels of biochemical indicators, hs-CRP levels, TIMI flow frame and the index of microcirculatory resistance (IMR) were examined, their relationships to SCF were analyzed. Results: Compared with Control group, the patients in SCF group showed the lower levels of HLL-C (1.57 ±0.38) mmol/L vs (1.62 ± 0.43) mmol/L and Apo-A1 (1.41 ± 0.31) mmol/L vs (1.57 ± 0.38) mmol/L, while higher level of hs-CRP (3.63 ± 1.67)μg/mL vs (1.74 ±0.75) μg/mL; SCF groups had increased IMR (29.28 ± 7.68) vs (24.94± 6.67), all P〈0.05. IMR was positively related to TIMI flow frame (r=0.766, P=0.019) and hs-CRP (r=0.565, P=0.000). Conclusion: ① Microcirculatory dysfunction was related to SCF. ② Inflammatory reaction, decreased blood levels of HDL-C and Apo-A 1 might be involved in pathological process of SCF.
出处 《中国循环杂志》 CSCD 北大核心 2016年第6期555-558,共4页 Chinese Circulation Journal
关键词 冠状动脉疾病 冠状动脉循环 血流速度 炎症 Coronary artery disease Coronary circulation Blood feow velocity Inflammation
  • 相关文献

参考文献12

  • 1Lim MJ , Kern MJ. Coronary pathophysiology in the cardiac catheterization laboratory. Curr Probl Cardiol, 2006, 31: 493-550.
  • 2Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary mierocirculation. Circulation, 2003, 107: 3129- 3132.
  • 3Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary mierocirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation, 2006, 113: 2054-2061.
  • 4Behrame JF. Defining the coronary slow flow phenomenon. Cire J, 2012, 76: 818-820.
  • 5Mangieri E, Macchiarelli G, Ciavlella M, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn, 1996, 37: 375-381.
  • 6Sezgin AT, Topal E, Barutcu l, et al. Impaired left ventricle filling in slow coronary flow phenomenon: an echo-Doppler study. Angiology, 2005, 56: 397-401.
  • 7Gonzalo J, Andy S, William F, et al. The index of mierocirculatory resistance in the physiologic assessment of the coronary microcirculation. Coronary Artery Disease, 2015, 26: e15-e26.
  • 8Lim HS, Yoon MH, Tahk SJ, et al. Usefulness of the index of microcirculatory resistance forinvasively assessing myocardial viability immediately after primary angioplasty for anterior myocardial infarction. Eur Heart J, 2009, 30: 2854-2860.
  • 9刘蓉,杨跃进,乔树宾,陈纪林,陈在嘉,高润霖,吴元,杨伟宪,赵冬云.高敏C反应蛋白对急性ST段抬高型心肌梗死患者近期预后的预测价值[J].中国循环杂志,2011,26(1):19-22. 被引量:70
  • 10李建军.C反应蛋白:动脉粥样硬化的标志物还是兼具致病作用[J].中国循环杂志,2009,24(4):241-243. 被引量:14

二级参考文献15

  • 1LI Jian-jun.Inflammation:an important mechanism for different clinical entities of coronary artery diseases[J].Chinese Medical Journal,2005(21):1817-1826. 被引量:53
  • 2Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation ,2002,105 : 1135-1143.
  • 3Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J,2000,21:1584-1590.
  • 4Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J,2005,26:241-249.
  • 5Tommasi S, Carluccio E, Bentivoglio M, et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol, 1999,83 : 1595-1599.
  • 6Mega JL, Morrow DA, De Lemos JA, et al. B-type natfiuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction : an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol, 2004,44:335-339.
  • 7Akkus MN, Polar G, Yurtdas M, et al. Admission levels of C-reac- tive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J,2009,50:33-45.
  • 8Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J, 2003,145 : 1094-1101.
  • 9Scifica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clinical Chemistry,2007,53 : 1800-1807.
  • 10Katayama T, Iwasaki Y, Yamamoto T, et al. "Smoker' s paradox" in patients with acute myocardial infarction receiving primary coronary intervention . Cardio1,2006,48 : 193-200.

共引文献80

同被引文献218

引证文献31

二级引证文献184

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部